Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

4 results
12:00 AM, Oct 08, 2012  |  BC Week In Review | Company News  |  Other News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

AVI-7537 was terminated due to funding constraints. Sarepta said the termination does not apply to AVI-7288
efficacy in relevant animal models and an acceptable safety risk profile in humans. AVI-7537 and AVI-7288
12:00 AM, Sep 10, 2012  |  BC Week In Review | Company News  |  Other News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

in Phase I testing to treat Ebola infection. The stop-work order does not apply to AVI-7288
which is being developed to treat Marburg virus under the same contract. AVI-7288 is a …
12:00 AM, Sep 10, 2012  |  BC Week In Review | Company News  |  Other News

Sarepta Therapeutics, U.S. Department of Defense infectious news

Project Manager Transformational Medical Technologies (JPM-TMT) program to evaluate the feasibility of intramuscular formulation of AVI-7288
evaluate safety, pharmacokinetics and efficacy of the formulation. Sarepta is developing an IV formulation of AVI-7288
under a separate DoD contract. AVI-7288 is a single oligomer nucleic acid analog based on morpholino-modified …
12:00 AM, Aug 13, 2012  |  BC Week In Review | Company News  |  Other News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

order, terminate the contracts or extend the stop-work order period. Sarepta is developing AVI-7537 and AVI-7288
phosphorodiamidate oligomers antisense chemistry. AVI-7537 is in Phase I testing to treat Ebola infection and AVI-7288